What a Key Person Clause Actually Does in a Regulation D Fund
A key person clause is a continuity mechanism built into the fund’s governing documents. It pauses new investment activity when a critical sponsor dies, becomes disabled, or stops running the fund – so the fund does not keep deploying capital while nobody the investors actually vetted is at the wheel.
That is the whole job. It is not a punishment, and it is not a self-destruct button. It buys time to fix a leadership problem before that problem turns into a bad deal.
The clause lives in the operating agreement and LPA legal package, alongside the rest of the fund’s governance terms. That is where the rules get written, and that is where sponsors most often get them wrong.
The Fundamental Misconception About Key Person Events
A lot of sponsors assume that if they die or become disabled, the fund automatically blows up and gets liquidated. That is not true, and you do not want it to be true.
Think about it from the investor’s side. Nobody who committed capital to a fund wants a fire sale of the portfolio the week the sponsor has a stroke. A forced liquidation at the worst possible moment destroys value for everyone.
What investors actually want is a structured transition. They want the fund to stop taking on new risk, keep the existing assets stable, and give someone a chance to bring in qualified replacement management.
So the purpose of the clause is not to end the fund. The purpose is to create a controlled pause so the parties can negotiate continuity instead of scrambling in a crisis.
The Mechanical Purpose: An Automatic Pause Button
The clause works as a sequence: trigger, suspension, cure, resolution. Something specific happens (the trigger), new investing stops (the suspension), the surviving team gets a window to fix it (the cure), and the fund either continues under new leadership or winds down (the resolution).
None of that is automatic under state law. You build it into the fund’s documents on purpose, tailored to how your fund actually operates and what your investors will accept.
The reason this matters comes down to whose capital is at risk. Investors backed a specific sponsor with a specific track record. If that person is gone, the last thing you want is a substitute manager – someone the investors never evaluated – writing checks and closing deals on their behalf.
The pause protects the investors from unvetted capital deployment. It also protects the surviving partners, because it gives them clear authority to stop rather than guess at what they are allowed to do in the middle of a disaster.
The Specific Events That Trigger a Key Person Clause
A key person event does not happen because something feels bad. It happens because a specific, defined event listed in the fund’s governing documents actually occurs. The most common triggers are death, permanent disability, and the named person’s failure to devote the required time and attention to the fund.
These triggers are contractual choices, not statutory rules. There is no securities law that tells you what counts as a key person event. You decide, and you write it into the Limited Partnership Agreement or operating agreement. That is why two funds down the street from each other can define the same event completely differently.
Permanent Incapacitation: Death and Disability
Death is the easy one. It is binary. The person is either alive or not, and there is rarely a fight about which.
Disability is where sponsors get sloppy. “Disability” means nothing until you define it, and a vague definition invites a fight at the worst possible time.
A well-drafted agreement ties disability to something objective. Either a physician certifies that the person can no longer perform their duties, or the person is unable to work for a set continuous period, like 60 or 90 consecutive days. Pick a standard you can actually measure.
What you do not want is a clause that triggers on “illness” or “inability to serve.” A named sponsor with the flu for two weeks should not hand your LPs an argument that a key person event occurred. Loose language turns a temporary problem into a fund-level crisis.
The ‘Time and Attention’ Requirement
The time-and-attention trigger is the business one. It fires when the named person walks away from the fund, usually to chase something new.
Say Bob is the named key person and, halfway through the investment period, he launches a competing fund and stops showing up. He is not dead. He is not disabled. But he has abandoned the mandate the limited partners (LPs) bought into, and a time-and-attention clause lets the fund respond.
The drafting tradeoff is real. You almost never want “100% exclusive time,” because most sponsors run more than one thing and everyone knows it. The workable standard is “substantially all business time reasonably necessary” to manage the fund. That preserves your flexibility to hold other assets while still giving LPs a trigger if you check out entirely.
Expect institutional LPs to negotiate this one hard. They are not worried about death – they are worried about you getting bored and moving on. Draft it so it protects them from abandonment without boxing you into a promise you cannot keep.
The Immediate Consequence: Suspending the Investment Period
A key person event does not terminate the fund. It suspends the investment period. The surviving management can no longer go out and buy new assets, but they must keep running the portfolio the fund already owns.
That distinction is the whole point. Investors are not asking for the fund to shut down and mail back checks. They are asking for a pause on new risk while everyone figures out who is running the show.
Pausing New Acquisitions and Capital Deployment
The primary rule of suspension is simple: no new deals close. Once the clause triggers, the manager loses the authority to commit fresh capital to new acquisitions.
The reason is that investors backed a specific person’s judgment. They read the Private Placement Memorandum, they looked at the key person’s track record, and they wired money based on the belief that this person would be the one selecting and executing deals.
Take that person out of the picture, and the mandate to deploy new capital evaporates. It does not matter that the surviving partners are competent. Investors did not underwrite them for the acquisition role, and they get a say before that changes.
There is a defensive benefit here for the surviving partners too. The suspension protects them. If they kept buying assets after the key person died or became disabled, an unhappy investor could later argue they deployed capital without authority. The automatic pause removes that argument. Nobody can say the surviving team went rogue, because the documents told them to stop.
Fulfilling Existing Legal Commitments and Active Capital Calls
The suspension stops new deals. It does not stop the fund from honoring commitments it already made.
The practical reality is that a fund cannot walk away from a signed contract just because a sponsor died. If the fund is under a binding purchase agreement, or has posted a hard-money deposit, the deal does not disappear. Defaulting on it would forfeit deposits and invite a breach-of-contract lawsuit.
So the exceptions to the suspension usually cover three things: deals already under binding contract, follow-on investments in assets the fund already holds, and existing debt obligations that come due. Capital calls can still go out for any of these.
Here is the reasoning. If a portfolio company needs a follow-on injection to survive, refusing to fund it would destroy value the investors already paid for. If a loan matures and the fund cannot make the payment, the lender forecloses. The suspension is meant to freeze forward growth, not to sabotage what the fund already owns.
A well-drafted clause spells out exactly which commitments survive the suspension. Leave that vague, and the surviving partners are stuck guessing whether a given capital call is allowed while investors and creditors pull in opposite directions.
The Cure Period: Replacing the Incapacitated Sponsor
The cure period is the structured window that lets the fund come back to life. The surviving sponsors use it to find and propose a qualified replacement manager, and the limited partners then vote on whether to accept that person. If the replacement gets approved, the suspension lifts and the investment period resumes.
Suspension is not the end of the story. It is the pause that buys time to fix the leadership gap. The cure period is where that fix either happens or fails.
Setting a Realistic Timeline for Replacement
A typical cure period runs 90 to 180 days. That is the window the surviving partners get to identify, vet, and present a replacement key person to the LPs.
Do not let anyone talk you into 30 days. Finding an institutional-grade manager, running real diligence on them, negotiating their terms, and getting them in front of investors does not happen in a month. If you set the window too short, you are effectively drafting an automatic path to liquidation, because nobody can realistically produce a qualified successor that fast.
The longer end of the range matters for the same reason. A 180-day window gives the survivors a fair shot at a good candidate instead of forcing them to grab whoever is available.
If the surviving partners fail to propose a replacement inside the window, the fund usually moves to dissolution. That is the default consequence, and it should be. The whole point of the clause is to avoid an indefinite limbo where capital sits frozen and nobody is authorized to run the portfolio.
Investor Voting Thresholds to Approve the Successor
Surviving sponsors cannot unilaterally install a new key person. That is the core protection here. The LPs invested in a specific manager, so the LPs get to decide whether the proposed successor is acceptable.
The required consent varies by fund. Most agreements require either a majority or a supermajority of the LP interests to approve the replacement. There is no universal number – it is a negotiated term, and institutional investors will push on it during diligence.
The threshold is a real tradeoff, and it cuts both ways.
Set it too low, and a bare majority can push through a successor that a large minority does not trust. Set it too high – say, 90% – and a tiny group of LPs can block the replacement and force the entire fund into an unwanted liquidation. A handful of holdouts should not be able to hold the surviving partners and every other investor hostage.
If it were me, I would land somewhere that gives the LPs a genuine say without handing a veto to a fringe. A majority or a reasonable supermajority of interests usually gets you there. The number you pick depends on your investor base and how concentrated your capital is, so this is worth thinking through before it ends up in the documents rather than after a key person is already gone.
The Critical Distinction: Key Person vs. For-Cause Removal
A key person event and a for-cause removal are not the same thing, and sponsors who confuse them create real problems for themselves. A key person event is a neutral continuity plan that responds to a tragedy or an operational shift. A for-cause removal is an adversarial action that investors take against a manager who did something wrong.
The difference is intent, and the difference is money.
Punitive Removal vs. Continuity Planning
For-cause removal requires a bad act. Fraud, a felony, willful misconduct, a serious breach of fiduciary duty, gross negligence – something that justifies stripping the sponsor of control. And because it is punitive, it usually strips the sponsor of economic rights too. The management fees stop. The carried interest can be reduced or forfeited. The whole point is that the manager did something to lose those rights.
A key person event is the opposite. Nobody did anything wrong. The named sponsor died, became disabled, or stopped devoting the required time. There is no bad act to punish. So the sponsor’s accrued economics and equity stay intact. The estate, the surviving partners, or the disabled sponsor keeps what they earned. The fund pauses new investments and looks for a replacement, but it does not confiscate anyone’s carry.
Here is the practical warning. If you draft a key person clause that behaves like a removal clause – meaning it wipes out economics when the key person simply dies – institutional capital reads that as a drafting mistake or, worse, as a sponsor who does not understand the difference. That is a red flag during due diligence. Sophisticated LPs expect these two provisions to look and function differently.
Why the Governing Documents Must Separate the Two
In a well-drafted Regulation D Operating Agreement, these are two distinct sections. Different triggers, different voting thresholds, different economic outcomes. For-cause removal gets a high bar to prove and a punitive result. A key person event gets an objective trigger and a preservation of economics. Keeping them separate is not stylistic – it is how you avoid an argument later about whether a sponsor’s death should cost the estate its carry.
The bigger danger is using generic LLC boilerplate that addresses neither. State default rules can treat a manager’s death as automatic dissociation. If your documents are silent, you may find the fund in legal limbo the moment the sponsor dies, with no defined pause, no cure period, and no clean path to a successor. That is exactly the chaos the key person clause is supposed to prevent.
If it were me, I would make sure the governing documents name both provisions explicitly and keep them in separate sections with separate consequences. You do not want investors treating a tragedy as if it were misconduct, and you do not want a state statute deciding your fund’s fate by default.
Mandatory Disclosures and Final Resolutions
Key person risk has to be disclosed in the Private Placement Memorandum, and the fund’s documents have to explain what happens if a replacement manager is never found. The mechanics we’ve covered only work if investors understood them going in. That understanding is what the PPM exists to create.
Disclosing Key Person Risk in the PPM
The rule is simple: a PPM must disclose every reasonably foreseeable risk, and the loss of a key person is one of the most foreseeable risks in any sponsor-driven fund.
Investors are buying the sponsor as much as the assets. If that sponsor dies or becomes disabled, the whole investment thesis changes. You cannot bury that in a footnote.
The illiquidity point matters just as much. Investors need to understand they are locked in. They cannot demand their money back just because the sponsor is gone, and the PPM has to say so plainly.
That is where a lot of sponsors get sloppy. They write a soft risk factor that hints at key person risk without spelling out the consequence. An investor reads it later, after a tragedy, and argues they were never told they’d be stuck.
Clear disclosure protects the surviving management. If the PPM said, in plain language, that the fund could suspend investments, seek a replacement, or wind down entirely on a key person event, and that investors could not redeem in the meantime, then nobody can later claim they were surprised.
Vague disclosure creates a failure-to-disclose problem you do not need. Precise disclosure closes that door.
Winding Down the Fund if No Replacement is Found
If the cure period runs out and no qualified replacement is approved, the fund shifts from a suspended investment period to liquidation.
That shift is mechanical, not chaotic. The surviving partners stop trying to run the fund forward and start running an orderly wind-down of the existing portfolio.
This is also what happens when the LPs vote down the proposed replacement. The surviving partners do not get to force a new manager on unwilling investors, so the remaining path is to sell the assets over a reasonable period and return capital.
An orderly wind-down almost always beats a fire sale. That’s the entire point of building the suspension and cure period in first: you buy time so nobody is forced to dump assets the week after a disaster.
Here’s the takeaway. A key person clause is not a doomsday device. It is a calm, predictable roadmap for an unpredictable event, and it gives everyone – surviving partners and investors alike – a way to protect value instead of panicking.
Tilden Moschetti, Esq., is a highly sought-after syndication attorney with nearly two decades of experience. His clientele ranges from real estate developers and startups to established businesses and private equity funds. Tilden’s expertise in syndication law comes not only from his knowledge of syndication and securities law but from real, hands-on experience as an active syndicator himself in every real estate product type and nearly all markets in the US. His knowledge and experience set him apart and established him as the Reg D legal services leader.


